Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал:
http://ir.librarynmu.com/handle/123456789/14796
Назва: | Features Of Coagulopathy And Systemic Inflammation In Patients After Covid-19 Infection |
Інші назви: | FEATURES OF COAGULOPATHY AND SYSTEMIC INFLAMMATION IN PATIENTS AFTER COVID-19 INFECTION |
Автори: | Mykhalchuk, D. Pavlovskyi, S. Pavlovska, M. Drozdov, V. Blagaia, A. |
Ключові слова: | COVID-19, Inflammation, Thrombolytic Therapy, Blood Platelets, Immunoglobulins, Interleukins |
Дата публікації: | 2022 |
Видавництво: | Wiadomości Lekarskie, VOLUME LXXV, ISSUE 12, DECEMBER 2022 |
Короткий огляд (реферат): | The aim: To determine the peculiarities of laboratory data concerning blood coagulation and systemic inflammation in COVID-19 patients in three months after discharge and recovery. The state of coagulation, anticoagulation, and fibrinolytic systems, as well as their prognostic value having been well studied in hospitalized COVID-19 patients, their state three months after hospitalization, are not yet well understood. Materials and methods: Methods of randomization, anthropometry, ECG, standard clinical blood testing, immunoenzymometry, immunoanalysis, and primary statistical analysis were used in the study. Anthropometric measurements of patients (n=20), blood samples, blood serum samples, urine samples, and statistical data were the materials of the study. Results: Indices of coagulation and systemic inflammation in studied patients after COVID-19 were obtained (PTT, s ; PATPT, s; Fibrinogen, g/L; Platelets ×109 /L; PCT, ng/mL; DD, μg/L; СRP, mg/L; IL -6, pg/mL; IL -10, pg/mL; Cortisol (nM/L); CIC (IU/mL); Ig A (g/L). Conclusions: Summing up the results obtained, it is possible to assert micro- and macro-vascular thromboses to be common in COVID-19 cases; they are associated with poor prognosis for diseased patients and are not completely investigated; the role of thromboses in COVID-19 course and complications are to be studied as well as the strategies of fibrinolytic therapies for such condition are to be justified. The presence of specific rheological and serological changes in patients even three months after surviving COVID-19 needs further study to understand the necessity of anti-thrombolytic drug uptake for a relatively long time. |
URI (Уніфікований ідентифікатор ресурсу): | http://ir.librarynmu.com/handle/123456789/14796 |
ISSN: | DOI: 10.36740/WLek202212103 |
Розташовується у зібраннях: | Наукові публікації кафедри гігієни та екології |
Файли цього матеріалу:
Файл | Опис | Розмір | Формат | |
---|---|---|---|---|
56 - WLek2022121_removed.pdf | 335,48 kB | Adobe PDF | Переглянути/Відкрити |
Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.